Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial

被引：0

作者：

Armstrong, Andrew J.

Haggman, Michael

Stadler, Walter Michael

Gingrich, Jeffrey R.

Assikis, Vasily J.

Polikoff, Jonathan

Denmeade, Samuel R.

George, Daniel J.

Andreou, Cal

Clark, William R.

Sieber, Paul

Agajanian, Richy

Belkoff, Laurence

Damber, Jan-Erik

Nordle, Orjan

Forsberg, Goran

Carducci, Michael Anthony

Pili, Roberto

机构：

[1] Duke Canc Inst, Durham, NC USA

[2] Uppsala Univ, Uppsala, Sweden

[3] Univ Chicago, Chicago, IL 60637 USA

[4] Univ Pittsburgh, Pittsburgh, PA USA

[5] Peachtree Hematol Oncol Consultants, Atlanta, GA USA

[6] Natl Surg Breast & Bowel Project, San Diego, CA USA

[7] Kaiser Permanente Southern Calif, San Diego, CA USA

[8] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[9] Andreou Res, Surrey, BC, Canada

[10] Alaska Clin Res Ctr, Anchorage, AK USA

[11] Urol Associates Lancaster Ltd, Lancaster, PA USA

[12] Agajanian Inst Onc & Hem, Whittier, CA USA

[13] Urol Consultants SE PA, Bala Cynwyd, PA USA

[14] Urologmottagningen, Gothenburg, Sweden

[15] Act Biotech, Lund, Sweden

[16] Johns Hopkins Univ Sch Med, Baltimore, MD USA

[17] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[18] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4550

引用

页数：1